Publications, Pharmaceutical

Using Bioequivalence and Particle Size Distribution to Develop OINDPs

The complexity of demonstrating bioequivalence in complex locally acting orally inhaled and nasal drug products is a barrier to the successful commercialization of generics.

This paper details a study to investigate the performance of a population bioequivalence (PBE) test based on particle size distribution measurements generated by morphologically directed Raman spectroscopy. Simulations of PBE trials were conducted across a range of median particle size and span values. Trial optimization strategies are presented based on the observed data and the general applicability of the approach is underlined. Appropriate trial design can help generic developers to avoid underpowered studies when using complex in vitro techniques to demonstrate bioequivalence.

Download Publication
6 Oct 2020

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

5 Jan 2023

Case Study – Unidose Nasal Spray Pump for Epilepsy

Case Studies, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
14 Dec 2022

Building Digital Solutions To Meet The Unique Therapeutic Needs o...

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
30 Nov 2022

Drug Repositioning – Benefits and Challenges for Lifecycle Mana...

Webinars, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Device Innovations

Read More
25 Nov 2022

Analytical Services in the Development of MDIs and DPIs

Brochures, Pharmaceutical, Innovation & Insights, Product Solutions

Read More
1 2 3 24
Back To Top